Kriya Therapeutics
CompanyUnited StatesFounded 2019
Kriya Therapeutics develops 2 assets, the furthest in phase 1 (VV-14299 in type 1 diabetes). Mostly gene therapy acting on Insulin/IGF-1 signalling, glycolysis and gck; based in the United States, founded in 2019.
- 2
- Assets
- Furthest stage
- Phase 1
- 3
- Trials
- 2
- Signals
Pipeline
2AAV vector-mediated delivery of glucokinase to promote glucose uptake
Phase 1, Gene therapy, Insulin/IGF-1 signalling, Glycolysis, type 1 diabetes
AAV vector expressing glucokinase injected into muscle to clear blood glucose
Phase 1, Gene therapy, Insulin/IGF-1 signalling, Glycolysis, type 1 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials3
- Signals2
- Similar companies6
Papers
A Twelve-Week Trial of MET097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist
ADA Scientific Sessions 2025 abstract, 13 Jun 2025